It also significantly reduced plasma galactitol levels in adults and children with galactosemia. Additional studies provided strong efficacy and safety data across 185 classic galactosemia ...
Hosted on MSN11mon
FDA extends review period for Applied Therapeutics’ govorestat NDAthe Phase I/II ACTION-Galactosemia study in adults; as well as preclinical findings. If approved, govorestat would become the first medication indicated for the treatment of galactosemia and aid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback